Japan's Daiichi Sankyo and US drugmaker MSD have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody...
Daiichi Sankyo and Merck & Co. to co-develop and commercialize three of Daiichi Sankyo’s DXd antibody-drug conjugate (ADC) candidates worldwide except for Japan where...
UK-Swedish drugmaker AstraZeneca has entered into a global development and commercialization agreement with Daiichi Sankyo, which could be worth up to $6 billion for the...
03.04.2019
- In a move to accelerate the development of its oncology franchise, AstraZeneca has agreed a $6.9 billion deal with Japanese pharma major Daiichi Sankyo to share rights to a new...
13.07.2015
- In another move to sharpen its focus on oncology, diabetes and respiratory disorders, AstraZeneca has announced it is selling all non-US rights for Entocort, a treatment for Crohn...
23.04.2015
- In a pre-negotiated share sale agreed a year ago, Japan's Daiichi Sankyo has unloaded its entire 8.9% stake in India's mammoth generics producer Sun Pharmaceutical Industries...
09.04.2014
- Sun Pharmaceutical Industries, India's largest drugmaker by market value, has agreed to buy compatriot generics manufacturer Ranbaxy Laboratories for $3.2 billion from Daiichi...
04.02.2014
- Japan's Daiichi Sankyo said it would send personnel to help resolve problems at a production facility of its drugmaking subsidiary Ranbaxy at Toansa in India's northern state of...
